Anthony Shields, M.D., Ph.D.

Specialties

Oncology - Medical

Subspecialties

Gastrointestinal Medical Oncology

Board Certification

American Board of Internal Medicine - Internal Medicine, Hematology and Medical Oncology

Multidisciplinary Team

Language(s) Spoken

English

Locations

Karmanos Cancer Center
4100 John R
Detroit, MI 48201
Get Directions

Phone:1-800-KARMANOS

Call For Appointment

Podcast: Listen

Cancers Treatments

Cancers Treated

Locations

Karmanos Cancer Center

4100 John R
Detroit, MI 48201
Get Directions

Phone:1-800-KARMANOS

Get Directions

Education

Cancers Treatments

Clinical Trials

A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of PBI-410 as Monotherapy and in Combination with Anti-Cancer Agents in Participants with Advanced Solid Tumors

Cancer Category
Age Group
Adult
Phase
Phase I/II

A Phase 1, Open-Label, Dose Escalation and Expansion Study of ASP1012, an Oncolytic Virus, in Participants with Locally Advanced or Metastatic Solid Tumors

Cancer Category
Gastrointestinal (GI),Gynecologic,Skin
Age Group
Adult
Phase
Phase I

A Randomized Phase 2b/Phase 3 Study of the TGF-B2 Targeting Antisense Oligonucleotide OT-101 in Combination with FOLFIRINOX Compared with FOLFIRINOX Alone in Patients with Advanced and Unresectable or Metastatic Pancreatic Cancer

Cancer Category
Gastrointestinal (GI)
Age Group
Adult
Phase
Phase II/III

A Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancr

Cancer Category
Gastrointestinal (GI)
Age Group
Adult
Phase
Phase I

A Phase 1/2, First-in-Human, Safety and Efficacy Study of NUV-1511 in Adult Patients with Advanced Solid Tumors

Cancer Category
Breast,Gastrointestinal (GI),Genitourinary (GU),Gynecologic
Age Group
Adult
Phase
Phase I/II

A Phase 1b Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ATP150/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in Patients With KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma (KISIMA-02)

Cancer Category
Gastrointestinal (GI)
Age Group
Adult
Phase
Phase I

A Phase 1, Open-Label Study of ABSK121 to Assess Safety, Tolerability, and Pharmacokinetics in Subjects with Advanced Solid Tumors

Cancer Category
Gastrointestinal (GI),Genitourinary (GU),Gynecologic
Age Group
Adult
Phase
Phase I

A Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients with Advanced Solid Tumors

Cancer Category
Breast,Gastrointestinal (GI),Genitourinary (GU),Gynecologic,Lung
Age Group
Adult
Phase
Phase I

A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemother

Cancer Category
Gastrointestinal (GI)
Age Group
Adult
Phase
Phase I/II

Use of [F-18] FLT for Imaging with Positron Emission Tomography (PET)

Cancer Category
Brain and Nervous System,Breast,Gastrointestinal (GI),Genitourinary (GU),Gynecologic,Head and Neck,Hematologic (Blood Cancers),Lung,Other,Sarcoma,Skin
Age Group
Adult
Phase
N/A

Additional Info

Dr. Shields' career has been dedicated to clinical research and the care of patients with colorectal, pancreatic and other gastrointestinal cancers. His experiences in research and the clinic make him painfully aware of the need to develop new approaches in understanding and overcoming resistance to treatment for patients with GI cancer. At Karmanos Cancer Institute and Wayne University School of Medicine he leads clinical research efforts through his roles as the Associate Center Director for Clinical Sciences, Program Leader in Molecular Imaging and Diagnostics and Professor of Oncology and Medicine. Dr. Shields training as a Medical Oncologist provides the insight to guide studies in patients with cancer and the foresight to design trials that are appropriate. He has a broad understanding in clinical sciences with experience that spans from protocol design and development to implementation from the local to the national level. He is the sub-chair for colorectal cancer at the Southwest Oncology Group (SWOG), and co-chair for a national adjuvant colon cancer study sponsored by the Cancer and Leukemia Group B (CALGB) and SWOG. He serves on the NCI Colon Task Force, which is charged with overseeing clinical research studies in colorectal cancer, and has served on the NCI Investigational Drug Steering Committee. In the clinic, his work concentrates on the treatment of patients with gastrointestinal (GI) cancer and he continues to develop and lead new clinical trials for GI tumors. This includes serving as a founding faculty member of the Clinical Trials Methodology Workshop under the sponsorships of the Radiological Society of North America (RSNA) and the National Cancer Institute, which is designed to mentor new faculty. As an Associate Center Director for Clinical Sciences, and member of the Human Investigation Committee Review Board, he helps to oversee a large number of clinical studies within our Institute and comprehends the complexities and challenges of the approaches to successful evaluation of new agents. Dr. Shields clearly has a crucial role in the design of cancer clinical trials. His laboratory research focuses on the development and testing of tracers for use with positron emission tomography (PET) for the assessment of a variety of tumors (e.g. brain, lung, breast, and prostate cancers) and their response to treatment. Dr. Shields led the development of FLT {3'-deoxy-3'-fluorothymidine}; a promising tracer for tumor proliferation, which has received an IND from the FDA and is being tested in centers worldwide. He serves on the Steering Committee of the American College of Radiology (ACRIN) and the National Oncology PET Registry (NOPR) and works to incorporate innovative imaging in the multicenter clinical trials. He is Senior Editor for Molecular Imaging and Biology and the Journal of Nuclear Medicine, and a reviewer for a number of journals, including the New England Journal of Medicine, Nature Medicine, and The Journal of Clinical Oncology. He has authored over 100 peer-reviewed articles and more than 20 book chapters, reviews and case reports on cancer research.

Related News

November 18, 2024
IN THE NEWS: A Full-Body MRI is the Latest Wellness Status Symbol. Should You Get One in 2025?

GQ Anthony Shields, M.D., Ph.D. , medical oncologist and member of the Gastrointestinal and Neuroendocrine Oncology and the Phase 1 Clinical Trials Multidisciplinary Teams at Karmanos, spoke to GQ about the imaging process for cancer screenings and his thoughts on full-body scans. Read the article here .
Read More
October 02, 2024
Hour Detroit’s 2024 Top Docs List Includes Over 50 Karmanos Physicians

Hour Detroit’s 2024 Top Docs List is out; over 50 physicians from the Barbara Ann Karmanos Cancer Institute are listed. Each year, Hour Detroit Magazine puts out an online peer-to-peer review survey conducted by Professional Research Services (PRS) to determine the top physicians in southeastern Michigan. Participating physicians in Livingston, Macomb, Oakland, Washtenaw, and Wayne Counties nominate the best doctors in each field. This year’s list also includes a feature with Elisabeth...
Read More
March 28, 2024
IN THE NEWS – Oncolytic Viruses: A Promising Cancer Treatment Option

Patient Power Many oncolytic viral therapy studies are being conducted, including some at Karmanos. Oncolytic viruses kill cancer cells while boosting immune response. Anthony Shields, M.D., Ph.D. , medical oncologist and member of the Gastrointestinal and Neuroendocrine Oncology and the Phase 1 Clinical Trials Multidisciplinary Teams, described how these therapies are used, possible side effects, and the ongoing investigations with oncolytic viral therapies, including one study that he and his colleagu...
Read More

Awards

2024 Detroit's Top Doctors, Hour Magazine
Heroes of Cancer Michael J. Brennan Award for Scientific Distinction, 2017
2005, 2009-2015 Voted one of the Best Doctor's in America by Best Doctors Inc.
2012, 2013 Selected by Castle Connolly Medical Ltd. as one of the region's Top Doctors
2007 Wayne State University Distinguished Faculty Fellowship Award
2005 European Association of Nuclear Medicine and Springer-Verlag Award - Best Clinical Paper
2005 Peter Valk Distinguished Clinical Scientist Award, Academy of Molecular Imaging

Professional Memberships

American Society of Clinical Oncology
American Society of Hematology
Society of Nuclear Medicine
American Association for Cancer Research
American Society for Microbiology
World Molecular Imaging Society

Publications

Wang J, Xiu J, Baca Y, Battaglin F, Arai H, Kawanishi N, Soni S, Zhang W, Millstein J, Salhia B, Goldberg RM, Philip PA, Seeber A, Hwang JJ, Shields AF, Marshall JL, Astsaturov I, Craig Lockhart A, Gatalica Z, Michael Korn W, Lenz HJ. Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. Oncogene. 2021 Jul;40(30):4894-4905. doi: 10.1038/s41388-021-01840-3. Epub 2021 Jun 23. PMID: 34163031
Wagner AJ, Severson PL, Shields AF, Patnaik A, Chugh R, Tinoco G, Wu G, Nespi M, Lin J, Zhang Y, Ewing T, Habets G, Burton EA, Matusow B, Tsai J, Tsang G, Shellooe R, Carias H, Chan K, Rezaei H, Sanftner L, Marimuthu A, Spevak W, Ibrahim PN, Inokuchi K, Alcantar O, Michelson G, Tsiatis AC, Zhang C, Bollag G, Trent JC, Tap WD. Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial. JAMA Oncol. 2021 Sep 1;7(9):1343-1350. doi: 10.1001/jamaoncol.2021.2086. PMID: 34236401
Vonderheide RH, Kraynyak KA, Shields AF, McRee AJ, Johnson JM, Sun W, Chintakuntlawar AV, Pawlicki J, Sylvester AJ, McMullan T, Samuels R, Kim JJ, Weiner D, Boyer JD, Morrow MP, Humeau L, Skolnik JM. Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors. J Immunother Cancer. 2021 Jul;9(7):e003019. doi: 10.1136/jitc-2021-003019. PMID: 34230114
Wang JY, Xiu J, Baca Y, Arai H, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Shields AF, Grothey A, Weinberg BA, Marshall JL, Lou E, Khushman M, Sohal DPS, Hall MJ, Oberley M, Spetzler D, Shen L, Korn WM, Lenz HJ. Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy. Ann Oncol. 2021 Jul;32(7):906-916. doi: 10.1016/j.annonc.2021.03.203. Epub 2021 Mar 30. PMID: 33798656
Meyerhardt JA, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Bendell JC, Kumar P, Lewis D, Tan B, Bertagnolli M, Grothey A, Hochster HS, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. JAMA. 2021 Apr 6;325(13):1277-1286. doi: 10.1001/jama.2021.2454. PMID: 33821899

Provider Profile:
Anthony Shields, M.D., Ph.D.